| C27 | Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trial | Oral abstract session with live Q&A | PrEP |
| C27 | Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase | Oral abstract session with live Q&A | PrEP |
| C27 | Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US | Oral abstract session with live Q&A | PrEP |
| C27 | Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW | Oral abstract session with live Q&A | PrEP |
| C57 | No impact of tenofovir/emtricitabine in estradiol exposure among transwomen on oral PrEP: results from the 12-week drug-drug interaction PrEParadas substudy | Oral abstract session with live Q&A | Prevention in transgender populations |
| C57 | Hormone levels among transgender women and transgender men in a transgender-led, integrated, gender-affirming care and sexual health service at Tangerine Clinic in Bangkok, Thailand: a real-world analysis | Oral abstract session with live Q&A | Prevention in transgender populations |
| C42 | Preference for long-acting injectable pre-exposure prophylaxis among transgender women clients of the Tangerine Clinic in Bangkok, Thailand | Oral abstract session with live Q&A | PrEP and transwomen |
| D2 | Factors associated with 12-month retention after referral to a differentiated service delivery for HIV treatment model in Zambia | Oral abstract session with live Q&A | Impact evaluation of differentiated service delivery |
| D51 | Community-led quality improvement of HIV services using community scorecards in Vietnam | Oral abstract session with live Q&A | Monitoring and evaluation of health systems |
| D33 | RAPID-VL intervention improves viral load ordering, results turnaround time and viral suppression: a cluster randomized trial in HIV clinics in Uganda | Oral abstract session with live Q&A | Scale up of viral load monitoring |